Clinicopathologic study of 37 cases of xanthelasma palpebrarum; clinical significance of xanthelasma palpebrarum in hyperlipidemiae and cardiovascular diseases

Korean Journal of Dermatology

Volumn 41, Issue 3, 2003, Pages 333-337

  Jee, Min Sun ^a   Chang, Sung Eun ^a   Choi, Jee Ho ^a   Sung, Kyung Jeh ^a   Moon, Kee Chan ^a   Koh, Jai Kyoung ^a  

^a University of Ulsan   (South Korea)

Author keywords

Cardiovascular disease; Dyslipoproteinemia; Hyperlipidemia; Xanthelasma palpebrarum

Indexed keywords

BIOCHEMICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; DYSLIPOPROTEINEMIA; EYELID XANTHELASMA; FEMALE; FOAM CELL; GIANT CELL; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; INFLAMMATORY CELL; LIPID BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MALE; XANTHOMATOSIS;

EID: 0038106076     PISSN: 04944739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 1994;30:236-242
2. Watanabe A., Yoshimura A., Wakasugi T., Tatami R., Ueda K., Ueda R., et al. Serum lipid, lipoprotein lipid and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 1981;38:283-290
3. Bates MC, Warren SG. Xanthelasma: clinical indicator of decresed levels of high-density lipoprotein cholesterol. Southern medical journal 1989;82:570-574
4. Segal P, Insull W Jr, Chambless LE, et al. The association of dyslipoprotenemia with corneal arcus and xanthelasma. Circulation 1986;73:108-1183
5. Parker F. Xanthomas. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors. Cutaneous medicine and surgery. Philadelphia; Sanunders, 1996, 1809-1817
6. Bergman R, Kasif Y, Aviram M, Maor I, Ullman Y, Gdalon M et al. Normolipidemic xanthelasma palaebrarum; lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 1996;76:107-110
7. Pinto X, Ribera M, Fiol C. Dyslipoproteinemia in patients with xanthelasma. Arch Dermatol 1989;125:1281-1282
8. Menotti A, Marcel YL, Seccareccia F. Determinants of all causes of death in samples of Italian middle-aged men followed up for 25 years. J Epidemiol Community Health 1987;41:243-250
9. Dean FD. Xanthelasma and hyperlipoproteinemia. Clinica Chimica Acta 1976;66:189-193
10. Pedace FJ., Winkelmann RK. Xanthelasma palpebrarum. JAMA 1965;193:893-894
11. Bergman R. Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 1998;37:343-349
12. Ronnen M, Sauster S, Huszar M, Gilad E. Treatment of xanthelasma with Solcodenn. J Am Acad Dermatol 1989;211:807-809
13. Yu DS, Oh CH, Song HJ. The use of pulsed dye laser for the treatment of xanthelasma palpebrarum. Ann Dermatol 2001;13:55-58